Glenmark Pharmaceuticals has said that its US arm has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Fenofibrate Capsules USP, 67 mg, 134 mg and 200 mg, the generic version of Tricor® Micronized Capsules, 67 mg, 134 mg, and 200 mg of AbbVie, Inc.
According to IMS Health sales data for the 12 month period ending February 2017, the Tricor® Micronized Capsules, 67 mg, 134 mg and 200 mg market1 achieved annual sales of approximately USD 97.5 million. Glenmark’s current portfolio consists of 114 products authorized for distribution in the U.S.
Nothing in any business is Risk Free but in Stock Market we can make you to work with lesser risk to make it happen what you want with simple click here >> http://www.ripplesadvisory.com/nifty-future-.php
Glenmark Pharmaceuticals has said that its US arm has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Fenofibrate Capsules USP, 67 mg, 134 mg and 200 mg, the generic version of Tricor® Micronized Capsules, 67 mg, 134 mg, and 200 mg of AbbVie, Inc.
No comments:
Post a Comment
Note: only a member of this blog may post a comment.